Johnson & Johnson vs Abbott Laboratories: Two Healthcare Giants on Opposite Trajectories
Quick Read JNJ’s 64-year dividend streak and oncology momentum make it the steadier buy, while ABT’s 18x forward…
Why Is The Market Punishing JNJ Stock?
The pharma division is firing on all cylinders, but a sudden crack in the MedTech business has the…
J&J falls despite a beat-and-raise quarter. Why we’re raising our price target anyways
Johnson & Johnson shares fell Tuesday despite a mostly strong second-quarter earnings report and an increase to its…
Market for psychedelic drugs to treat mental health gets a buy signal
Psilocybin mushrooms stand ready for harvest in a humidified “fruiting chamber.” John Moore | Getty Images Thursday’s announcement…
Meta’s latest move in the AI talent war, plus Cramer’s 4 quick hits
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…
Johnson & Johnson (JNJ) Q2 earnings
Johnson & Johnson beat Wall Street estimates for second-quarter sales and profit on Wednesday, as strong growth from…
Johnson & Johnson has a chance to show it’s more than just a rotation winner
Johnson & Johnson shares have showed signs of life ahead of earnings. For the stock to keep running,…
Eli Lilly, Regeneron in FDA PreCheck manufacturing program
Eli Lilly and Regeneron are among the first seven companies the U.S. Food and Drug Administration selected for…
64 With $1.1 Million in a Traditional IRA. Yield Volatility Is Back. Here’s Where I’m Allocating Capital
Quick Read JNJ and PG anchor a three-stock Dividend King allocation targeting tax-deferred income inside a $1.1M IRA…
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Choosing between established healthcare giants often comes down to balancing income needs against growth potential. Both Bristol Myers…
The AI trade cooled and oil sank. A closer look at Wall Street’s volatile week
Wall Street spent the week debating who the biggest winners and losers of the artificial intelligence boom will…
We’re trimming a stock into strength, raising our price target
We are selling 50 shares of Cardinal Health at roughly $235. Following the trade, Jim Cramer’s Charitable Trust…